查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球抗菌藥物敏感性測試市場-2022-2029
市場調查報告書
商品編碼
1146441

全球抗菌藥物敏感性測試市場-2022-2029

Global Antimicrobial Susceptibility Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），全球抗菌藥物敏感性測試市場規模預計將以 5.4% 的複合年增長率增長。

抗菌藥物敏感性測試 (AST) 是一種實驗室技術，醫學和臨床實驗室技術人員使用該技術來確定哪些抗生素治療方案對個體患者最有效。它還用於評估醫院、診所和國家傳染病控制和預防計劃的治療服務。

市場動態

技術進步、傳染病流行、政府和私人組織增加研發資金以及醫療保健基礎設施的進步推動了全球抗菌藥物敏感性測試市場的增長。

全球對抗菌藥物敏感性測試的需求不斷增長，正在推動市場增長

抗菌素耐藥性 (AMR) 已成為全球公共衛生的主要威脅。根據世界衛生組織 (WHO) 的數據，世界所有地區的抗生素耐藥性已經上升到危險的高水平，導致發病率和死亡率上升。世界銀行還估計，耐藥性感染將引發全球經濟危機，到 2050 年每年將有 2800 萬人陷入極端貧困，每年使整個全球經濟損失 1 萬億美元。我在這裡。

為了控制 AMR 的發生和傳播，準確、及時地檢測抗菌藥物耐藥性並在抗菌藥物管理的基礎上實施適當的抗菌治療非常重要。細菌感染的最佳治療依賴於 AST 結果，這是每個臨床微生物實驗室日常工作的一部分。本報告將提供對區域抗菌藥物敏感性模式的了解，並幫助醫療保健專業人員選擇最有效的抗菌治療方法。例如，如果一種藥物的 AMR 率大於 20%，則不應單獨使用該藥物作為治療感染的經驗性療法。

此外，市場參與者正在採用收購和產品發布等市場策略。例如，2022 年 4 月，BIOMERIEUX 同意收購 Specific Diagnostics。這家美國私人控股公司是 SPECIFIC REVEAL Rapid AST 系統的開發商，該系統是一種快速抗菌藥敏試驗 (AST)，可直接從陽性血培養中提供表型 AST。此外，2020 年 2 月，Bio-Rad Laboratories, Inc. 收購了診斷產品開發商和製造商 Exact Diagnostics, Inc.，以確保測試結果的有效性和一致性。對 Exact Diagnostics 的收購使 Bio-Rad Laboratories, Inc. 可以獲得移植、呼吸系統、病毒學、微生物學、性傳播疾病和病媒傳播疾病領域的分子質量控制產品的綜合目錄。

抗菌藥敏測試產品/設備的弱點阻礙市場增長

但是，除了成本高之外，分子生物學方法的主要缺點是只能通過可用的探針檢測靶向抗性基因，而且抗性基因不一定與抗性表型的表達相關，不要高估你的耐受性。此外，自動化和半自動化系統具有固有的優勢和局限性，抗生素、軟件版本和卡片之間的結果可能會有很大差異。因此，某些系統可能無法正確分類特定藥物的敏感性特徵，從而導致敏感性類別的錯誤分類。似乎低接種量會極大地影響這些系統的結果，導致錯誤地報告易感性。

COVID-19 影響分析

COVID-19 大流行影響了 AMR 的監測、預防和控制，因為與 AMR 的合作有限、資金減少以及護理、醫療和公共衛生人員的利用率不足。稻田。根據臨床實驗室標準協會 (CLSI) 2020 年報告，需要快速診斷來確定患者是否患有傳染病，確定病毒或細菌感染的來源，並確定病因及其易感性特徵，非常需要。通過快速識別可疑病原體並確定其對治療的敏感性，實驗室可以在快節奏的環境中指導適當的一線臨床決策。這不僅大大改善了個體的預後，而且避免了不必要的抗生素使用。此外，增加使用洗手液和表面清潔劑等消毒劑預計將在未來幾年增加具有抗菌素耐藥性的病原微生物的比例。

細分分析

在預測期內（2022-2029 年），自動化實驗室設備領域預計將以最快的複合年增長率增長

自動化實驗室設備市場份額最大。根據 2022 年發表在《抗生素雜誌》上的一篇文章，目前用於快速 AST 的技術包括市場上基於微量稀釋敏感性測試的自動化和半自動化儀器。例如，Phoenix System 被臨床微生物實驗室廣泛接受並用於鑑定和抗菌藥敏試驗。它使用氧化還原指示劑（阿拉瑪藍和刃天青染料），並採用在各種濃度的抗菌劑存在下通過檢測細菌生長來確定易感性的原理。 Microscan Walkaway Plus 系統還為各種革蘭氏陽性和革蘭氏陰性需氧菌提供準確、快速的鑑定和藥敏結果。

此外，AutoSCAN-3 可用作第一代 Microscan 無人值守系統。新版本的 Auto-ACAN-4 和 AutoSCAN-WalkAway 儀器已經過改進，並使用不需要冷藏的干燥面板。 AutoSCAN-WalkAway 是一種檢測細菌□活性的系統，可以同時處理 96 個面板。 AST 先進自動化系統的出現刺激了全球市場。

區域分析

北美在全球抗菌藥物敏感性測試市場中佔有最大的市場份額。

北美在抗菌藥物敏感性測試市場中占主導地位，預計在預測期內將呈現類似趨勢。北美抗菌藥物敏感性測試市場的增長歸因於技術進步、傳染病數量的增加、產品推出的增加以及主要參與者的存在。

根據 bioMerieux 組織的數據，美國每年發生超過 280 萬例抗生素耐藥性感染。耐藥菌的出現是一種不可預知的現象，由於抗生素使用不當而加劇和加速。該地區不斷增加的抗菌藥物敏感性測試正在推動市場。

此外，市場參與者正在採用收購和產品發布等市場策略。例如，2022年5月，Accelerate Diagnostics宣布新產品“Accelerate Arc Module”和“BC Kit”的商業化。 Accelerate Arc Module 和 BC 試劑盒是在線離心和自動化樣品製備技術的一種新應用，與血液培養試劑盒一起，可提供可直接轉移到 MALDI 點樣板上的經過洗滌的微生物細胞懸浮液。此外，Accelerate PhenoTest BC 試劑盒 AST 配置使實驗室能夠比當前標準方法提前幾天直接報告陽性血培養的鑑定和抗菌藥敏試驗結果。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 感染增加
      • 技術進步
    • 限制因素
    • 嚴格的規定
    • 商機
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 手動抗菌藥敏試驗產品
    • 藥敏試驗盤
    • MIC 條
    • 靈敏度測試板
  • 自動檢測設備
  • 消耗品

第 8 章方法

  • 肉湯稀釋法
  • 快速自動化方法
  • 圓盤擴散法
  • 梯度擴散法
  • 分子檢測方法

第 9 章按測試類型

  • 抗菌
  • 抗真菌劑
  • 驅蟲劑
  • 其他

第 10 章按應用程序

  • 臨床診斷
  • 藥物發現和開發
  • 其他

第 11 章最終用戶

  • 診斷中心/醫院
  • 製藥和生物技術公司
  • 合同研發組織 (CRO)
  • 研究和學術機構

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 14 章公司簡介

  • bio Merieux S.A.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Merck Group
  • HiMedia Laboratories
  • Alifax Holding S.p.A.
  • Creative Diagnostics
  • Synbiosis

第 15 章全球抗菌藥物敏感性測試市場數據M

簡介目錄
Product Code: DMCD1107

Market Overview

The global antimicrobial susceptibility testing market size was growing at a CAGR of 5.4% during the forecast period (2022-2029).

Antimicrobial susceptibility testing (AST) is a laboratory technique conducted by medical technologists or clinical laboratory scientists to determine which antimicrobial regimen is particularly efficacious for individual patients. On an enormous scale, it helps evaluate treatment services delivered by hospitals, clinics, and national programs for managing and preventing infectious diseases.

Market Dynamics

The global antimicrobial susceptibility testing market growth is driven by technological advancement, a rising prevalence of infectious disease, rising funding for research and development from government and private organizations, and advancements in healthcare infrastructure.

The rising need for antimicrobial susceptibility testing across the globe drives the market growth

Antimicrobial resistance (AMR) has appeared as a major threat to public health worldwide. According to the World Health Organization (WHO), antibiotic resistance is rising to dangerously high levels in all regions of the world, leading to raised morbidity and mortality. In addition, the World Bank estimates that drug-resistant infections could induce a global economic crisis, leading to 28 million people who could be moved into extreme poverty every year by 2050, with an overall cost to the global economy of USD 1 trillion per year.

Exact and quick detection of resistance to antimicrobial drugs and following appropriate antimicrobial treatment, incorporated with antimicrobial stewardship, are crucial for controlling the emergence and spread of AMR. The best therapeutic option for treating bacterial infections relies on the results of AST, a part of the routine work of all clinical microbiological laboratories. Reports provide an understanding of local antimicrobial susceptibility patterns, helping healthcare professionals select the most effective antibiotic therapy. For instance, if the AMR rate of a pathogen is above 20%, that drug should not be administered as a single empiric therapy for infection treatment.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in April 2022, BIOMERIEUX agreed to acquire Specific Diagnostics. This privately held U.S.-based company has developed a rapid antimicrobial susceptibility test (AST), SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures. Moreover, in February 2020, Bio-Rad Laboratories, Inc. acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalog of molecular quality control products in transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

The drawbacks of antimicrobial susceptibility testing products/instruments will hamper the growth of the market

However, besides high costs, major drawbacks of molecular methods are the detection of the resistance genes targeted only by the available probes and overestimating resistance because the resistance gene is not necessarily associated with the expression of a resistance phenotype. In addition, automated and semi-automated systems have inherent advantages and limitations, and the results vary widely by antimicrobial drugs, software versions, and cards. Hence, some systems are unreliable for correctly categorizing susceptibility profiles for certain drugs, leading to wrong classifications of susceptibility categories. It appears that small inoculum size significantly influences the outcome of these systems, with false susceptibilities being reported.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the limited ability to work with AMR partnerships decreased funding, and reduced availability of nursing, medical, and public health staff affected AMR surveillance, prevention, and control. According to the Clinical and Laboratory Standards Institute (CLSI) 2020 report, there is a critical need for rapid diagnostics to determine if a patient has an infection, determine viral and bacterial sources, and identify the etiologic agent and its susceptibility profile. Labs can guide the right-first-time clinical decisions in fast-paced environments by fast identifying the suspected pathogen and determining its susceptibility to treatment. Not only can this significantly improve individual outcomes, but the approach also avoids unnecessary antibiotic use. In addition, increased use of disinfectants, including hand sanitizers and surface cleaners, is anticipated to cause inflated rates of antimicrobial resistance in pathogenic microbes in the coming years.

Segment Analysis

The automated laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The automated laboratory instruments segment accounts for the largest market share. As per the article published in Antibiotics Journal in 2022, current technologies for rapid AST are available in the market, including automated and semi-automated devices based on microdilution susceptibility testing. For instance, the Phoenix System is widely accepted and used in clinical microbiology laboratories for identification and antimicrobial susceptibility testing. The principle of determining the susceptibility is based on using an oxidation-reduction indicator (Alamar blue or resazurin dye) and detecting bacterial growth in the presence of various concentrations of the antimicrobial agent. Also, The MicroScan WalkAway plus System provides accurate and rapid identification and susceptibility results for a wide range of Grampositive and Gram-negative aerobic bacteria.

In addition, The first generation of the MicroScan WalkAway System available on the market is the AutoSCAN-3. The new versions of instruments Auto-ACAN-4 and AutoSCAN-WalkAway are improved and use dry panels that do not need refrigeration. The AutoSCAN-WalkAway system detects bacterial enzymatic activity and can process 96 panels simultaneously. The availability of advanced and automated systems for AST boosts the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global Antimicrobial Susceptibility Testing market

North America dominates the market for antimicrobial susceptibility testing and is expected to show a similar trend over the forecast period. The growth of the North American antimicrobial susceptibility testing market can be attributed to technological advancements, rising infectious disease, increasing launching of products and the presence of key players.

According to the bioMerieux organization, more than 2.8 million antibiotic-resistant infections occur annually in the United States. The emergence of resistant bacteria is an unpretending phenomenon worsened and accelerated by the improper use of antibiotics. Rising antimicrobial susceptibility testing in the region drives the market.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2022, Accelerate Diagnostics, Inc. announced the commercialization of its new Accelerate Arc Module and BC kit. The Accelerate Arc Module and BC kit is a new application of inline centrifugation and automated sample prep techniques, which, together with the blood culture kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. In addition, Accelerate PhenoTest BC kit AST configuration enables laboratories to report identification and antimicrobial susceptibility test results directly from positive blood cultures days earlier than current standard-of-care methods.

Competitive Landscape

The antimicrobial susceptibility testing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are bioMerieux S.A., Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck Group, HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, and Synbiosis, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global antimicrobial susceptibility testing market.

For instance,

  • In October 2021, Thermo Fisher Scientific and Q-linea launched ASTar Technology, a quick antimicrobial susceptibility testing (AST) system that provides true minimum inhibitory concentration (MIC) data in less than 6 hours. Conventional AST techniques might take up to 72 hours to obtain findings.

bioMerieux SA

Overview:

bioMerieux SA is an organization that provides solutions for microbiology, which is used in clinical labs to provide effective results because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.

Product Portfolio:

VITEK 2: It is an automated susceptibility testing system capable of determining the extensive majority of routine organisms (around 300 microorganisms). This system gives results within hours due to the combination of analysis software and an original, miniaturized consumable. This testing system is available for a various range of microorganisms.

The global antimicrobial susceptibility testing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Infectious Diseases
      • 4.1.1.2. Technological Advancements
    • 4.1.2. Restraints:
    • 4.1.3. Strict Regulatory Procedures
    • 4.1.4. Opportunity
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Manual Antimicrobial Susceptibility Testing Products*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Susceptibility Testing Disks
    • 7.2.4. MIC Strips
    • 7.2.5. Susceptibility Plates
  • 7.3. Automated Laboratory Instruments
  • 7.4. Consumables

8. By Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 8.1.2. Market Attractiveness Index, By Method
  • 8.2. Broth Dilution Method*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Rapid Automated Method
  • 8.4. Disk Diffusion Method
  • 8.5. Gradient Diffusion Method
  • 8.6. Molecular Testing Method

9. By Test Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.1.2. Market Attractiveness Index, By Test Type
  • 9.2. Antibacterial*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Antifungal
  • 9.4. Antiparasitics
  • 9.5. Others

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Clinical Diagnosis*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Drug Discovery and Development
  • 10.4. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Diagnostic Centers and Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Pharmaceutical and Biotechnology Companies
  • 11.4. Contract Research Organizations (CROs)
  • 11.5. Research and Academic Institutes

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking

14. Company Profiles

  • 14.1. bioMerieux S.A.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Danaher Corporation
  • 14.3. Becton, Dickinson and Company
  • 14.4. Thermo Fisher Scientific Inc.
  • 14.5. Bio-Rad Laboratories Inc.
  • 14.6. Merck Group
  • 14.7. HiMedia Laboratories
  • 14.8. Alifax Holding S.p.A.
  • 14.9. Creative Diagnostics
  • 14.10. Synbiosis

LIST NOT EXHAUSTIVE

15. Global Antimicrobial Susceptibility Testing Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us